Results 181 to 190 of about 26,198 (235)

Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study. [PDF]

Nephrology (Carlton)
Inoue R, Yamaguchi S, Okada A, Yamauchi T, Kadowaki T, Nangaku M.   +5 more
europepmc   +1 more source

Mechanism of xanthine oxidase in flap ischemia-reperfusion injury and advances in targeted therapy: a mini review. [PDF]

Front Physiol
Jia W, Wei X, Gong X.
europepmc   +1 more source

HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US.

JAMA Dermatol
Campbell CN, Krantz MS, Yu A, Phillips EJ, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Survivor Study Collaborators.   +4 more
europepmc   +1 more source

Clinical Impact of Febuxostat in HFpEF Versus HFrEF: Insights from a Prospective Cohort. [PDF]

Balkan Med J
Ahsaan F, Latif B, Rehman Z.
europepmc   +1 more source

Aqueous and methanol extracts of Paullinia pinnata improve MSUc uptake in macrophages and in vitro antioxidant effects. [PDF]

Sci Rep
Tseuguem PP, Nguelefack TB, Nguelefack-Mbuyo EP, Kenne IDT, Pouadjeu JM, Piegang BN.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Low-Dose Colchicine Prophylaxis When Starting Allopurinol Using the "Start-Low Go-Slow" Approach for Gout: Evidence From a Noninferiority Randomized Double-Blind Placebo-Controlled Trial. [PDF]

Arthritis Care Res (Hoboken)
Pryymachenko Y, Wilson R, Dalbeth N, Abbott JH, Stamp L.   +4 more
europepmc   +1 more source

Allopurinol in Dermatology

American Journal of Clinical Dermatology, 2010
Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has spurred renewed interest in its application in other clinical specialties.
Tsen-Fang, Tsai, Ting-Yu, Yeh
openaire   +3 more sources

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response

Clinical and Experimental Allergy, 2013
BACKGROUND Allopurinol is a main cause of severe cutaneous adverse reactions (SCAR). How allopurinol induces hypersensitivity remains unknown. Pre-disposing factors are the presence of the HLA-B*58:01 allele, renal failure and possibly the dose taken.
Carlo R Largiadèr, D Yerly
exaly   +2 more sources

Allopurinol and oxypurinol are hydroxyl radical scavengers

FEBS Letters, 1987
Allopurinol is a scavenger of the highly reactive hydroxyl radical (k2 approx. 109 M−1s−1). One product of attack of hydroxyl radical upon allopurinol is oxypurinol, which is a major metabolite of allopurinol.
Martin Grootveld, Barry Halliwell
exaly   +2 more sources